Published in Vaccine on November 12, 1999
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun (2003) 1.06
Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun (2009) 0.94
Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun (2001) 0.88
Low-volume jet injection for intradermal immunization in rabbits. BMC Biotechnol (2002) 0.82
A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice. PLoS Negl Trop Dis (2014) 0.82
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genet Vaccines Ther (2005) 0.81
Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques. Hum Vaccin Immunother (2013) 0.78
Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus. Virol J (2009) 0.77
Expression library immunization: a road map for discovery of vaccines against infectious diseases. Infect Immun (2005) 0.76
Technical transformation of biodefense vaccines. Vaccine (2009) 0.75
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation (1995) 5.06
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Consensus criteria for traumatic grief. A preliminary empirical test. Br J Psychiatry (1999) 2.75
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun (1996) 2.17
Vaccination against bubonic and pneumonic plague. Vaccine (2001) 2.08
Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun (1995) 2.04
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Spread of prostatic cancer to bone. Urology (1983) 1.94
Seizures associated with antidepressants: a review. J Clin Psychiatry (1993) 1.91
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun (1997) 1.77
The activity of enviroxime against rhinovirus infection in man. Lancet (1981) 1.66
Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet (1982) 1.66
Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine (2001) 1.60
Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst (1993) 1.54
Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol (1977) 1.53
Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirus. J Virol Methods (1983) 1.43
The use of bladder for total transplant ureteral reconstruction. J Urol (1998) 1.40
Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol (1996) 1.39
Influence of traumatic grief on suicidal ideation among young adults. Am J Psychiatry (1999) 1.38
Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol (1983) 1.35
The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol (1999) 1.31
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
Perspectives on care at the close of life. Caring for bereaved patients: "all the doctors just suddenly go". JAMA (2001) 1.30
Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun (1995) 1.29
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Quality of life impairments associated with diagnostic criteria for traumatic grief. Psychol Med (2000) 1.28
Decreased 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients. J Urol (1996) 1.27
Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine (2000) 1.22
Purified interferon as protection against rhinovirus infection. Br Med J (Clin Res Ed) (1982) 1.21
Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog (1997) 1.18
Some further studies on the prediction of experimental colds in volunteers by psychological factors. J Psychosom Res (1984) 1.18
The detrimental effect of poor early graft function after laparoscopic live donor nephrectomy on graft outcomes. Am J Transplant (2008) 1.17
Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. J Urol (1997) 1.16
Virus isolation studies in Crohn's disease: a negative report. Gut (1979) 1.16
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
The pH 6 antigen of Yersinia pestis binds to beta1-linked galactosyl residues in glycosphingolipids. Infect Immun (1998) 1.15
Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response. Am J Psychiatry (2000) 1.15
The measurement of grief: bereaved versus non-bereaved. Hosp J (1986) 1.15
Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine (2003) 1.13
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
The influence of marital quality and attachment styles on traumatic grief and depressive symptoms. J Nerv Ment Dis (1998) 1.09
Retrograde method for percutaneous access to kidney. Urology (1983) 1.09
Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun (1997) 1.08
Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol (1998) 1.07
Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J Pharm Pharmacol (2001) 1.07
Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. A mechanism for irradiation erythema. J Clin Invest (1990) 1.06
Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett (1994) 1.06
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
Molecular variation between the alpha-toxins from the type strain (NCTC 8237) and clinical isolates of Clostridium perfringens associated with disease in man and animals. Microbiology (1996) 1.04
Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol (1998) 1.03
Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother (1983) 1.03
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine (1998) 1.03
A search for persistent virus infection in Crohn's disease. Gut (1980) 1.03
Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathog (2004) 1.02
The efficacy of relaxation response interventions with adult patients: a review of the literature. J Cardiovasc Nurs (1996) 1.02
An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology (1996) 1.02
A diagnostic in vitro urine assay for interstitial cystitis. Urology (1998) 1.02
Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother (1985) 1.01
Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report. Arch Virol (1987) 1.00
Production of a non-toxic site-directed mutant of Clostridium perfringens epsilon-toxin which induces protective immunity in mice. Microbiology (1998) 1.00
An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2. Antiviral Res (1983) 0.98
Nuclear and nucleolar localization of an African swine fever virus protein, I14L, that is similar to the herpes simplex virus-encoded virulence factor ICP34.5. J Gen Virol (1999) 0.98
Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue. Biochem Biophys Res Commun (1987) 0.97
Biochemical and immunological properties of the C-terminal domain of the alpha-toxin of Clostridium perfringens. FEMS Microbiol Lett (1993) 0.97
Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol (1999) 0.97
An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine (2000) 0.97
Laparoscopic nephrectomy in the markedly obese living renal donor. Urology (2000) 0.96
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate (2001) 0.95
Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb Pathog (1999) 0.95
Epitope mapping of the alpha-toxin of Clostridium perfringens. Infect Immun (1991) 0.95
Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res (1999) 0.94
Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother (1983) 0.94
Prostatic osteoblastic factor. Invest Urol (1979) 0.94
Helical computerized tomography arteriography for evaluation of live renal donors undergoing laparoscopic nephrectomy. J Urol (1999) 0.94
Ureteral injury due to blunt and penetrating trauma. Urology (1992) 0.93
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 0.93
African swine fever virus gene j13L encodes a 25-27 kDa virion protein with variable numbers of amino acid repeats. J Gen Virol (1995) 0.93
The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol (2000) 0.93
Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol (2001) 0.92
Expression of a recombinant form of the V antigen of Yersinia pestis, using three different expression systems. Vaccine (1999) 0.92
Primary signet-ring cell carcinoma of the urinary bladder. Cancer (1984) 0.92
Pathologic effects of pre-cystectomy therapy with combination intra-arterial doxorubicin hydrochloride and local bladder hyperthermia for bladder cancer. J Urol (1982) 0.92
Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine (2004) 0.91
The effects of cognitive impairment on 9-year mortality in a community sample. J Gerontol B Psychol Sci Soc Sci (1995) 0.90
Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup. J Urol (1998) 0.90
Rhinovirus colds. Br Med Bull (1985) 0.90
Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res (1984) 0.89
Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev (2001) 0.88
Warm ischemia time does not correlate with recipient graft function in laparoscopic donor nephrectomy. Surg Endosc (2003) 0.88
Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J Gen Virol (1985) 0.88
Primary renal carcinoid tumor. Urology (1988) 0.88
The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses. Clin Exp Immunol (2007) 0.87
Congenital renal arteriovenous malformations. Urology (1981) 0.87
Influence of maternal grooming, sex and age on Fos immunoreactivity in the preoptic area of neonatal rats: implications for sexual differentiation. Dev Neurosci (1997) 0.87
The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses. Microb Pathog (2000) 0.86
Distribution of productive antigen-processing activity for MHC class II presentation in macrophages. Scand J Immunol (2005) 0.86
Bereavement and catecholamines. J Psychosom Res (1986) 0.86